ВАРИАБЕЛЬНОСТЬ АРТЕРИАЛЬНОГО ДАВЛЕНИЯ ПРИ КОМОРБИДНОСТИ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ И ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ

  • С. С. Боев Запорожская медицинская академия последипломного образования, Запорожье, Украина https://orcid.org/0000-0003-0416-1605
  • Н. Я. Доценко Запорожская медицинская академия последипломного образования, Запорожье, Украина https://orcid.org/0000-0003-4858-1791
  • И. А. Шехунова Запорожская медицинская академия последипломного образования, Запорожье, Украина https://orcid.org/0000-0001-7661-4904
  • Л. В. Герасименко Запорожская медицинская академия последипломного образования, Запорожье, Украина https://orcid.org/0000-0002-1250-7162
  • О. В. Яценко Запорожский государственный медицинский университет, Запорожье, Украина https://orcid.org/0000-0002-5225-2512
  • Д. Ю. Любитов Городская больница скорой медицинской помощи, Каменское, Украина https://orcid.org/0000-0001-5736-5770
Ключевые слова: артериальная гипертензия, фибрилляция предсердий, вариабельность артериального давления

Аннотация

Введение. Артериальная гипертензия играет решающую роль в развитии фибрилляции предсердий, являясь наиболее важным фактором риска. Цель. Провести анализ литературы по современным представлениям о взаимосвязи вариабельности артериального давления и фибрилляции предсердий. Материал и методы. Проанализированы 53 литературных источника. Результаты. Получены сведения о современных механизмах формирования фибрилляции предсердий при артериальной гипертензии. Освещены подходы к выбору антигипертензивной терапии у пациентов с артериальной гипертензией и фибрилляцией предсердий. Выводы. На основе изученных исследований в представленной литературе установлено, что вариабельность артериального давления несет дополнительный вклад в сердечно-сосудистый риск. Снижение вариабельности артериального давления может быть добавлено в качестве одной из важных стратегий в терапии артериальной гипертензии и фибрилляции предсердий.

Литература

Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962. https://doi.org/10.1093/eurheartj/ehw210.

Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, Witteman JC, Stricker BH, Heeringa J. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34(35):2746-51. https://doi.org/10.1093/eurheartj/eht280.

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):e13-e115. https://doi.org/10.1161/HYP.0000000000000065.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-72. https://doi.org/10.1001/jama.289.19.2560.

Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-23. https://doi.org/10.1016/S0140-6736(05)17741-1.

January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. 2014 AHA/ACC/ HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071-2104. https://doi.org/10.1161/CIR.0000000000000040.

Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-952. https://doi.org/10.1161/01.cir.98.10.946.

Miyasaka Y, Barnes ME, Bailey KR, Cha SS, Gersh BJ, Seward JB, Tsang TS. Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year communitybased study. J Am Coll Cardiol. 2007;49(9):986-992. https://doi.org/10.1016/j.jacc.2006.10.062.

Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA, Thacker EL, Judd S, Howard VJ, Howard G, Herrington DM, Cushman M. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 2014;174(1):107-114. https://doi.org/10.1001/jamainternmed.2013.11912.

Soliman EZ, Lopez F, O’Neal WT, Chen LY, Bengtson L, Zhang ZM, Loehr L, Cushman M, Alonso A. Atrial Fibrillation and Risk of ST-Segment-Elevation Versus Non-ST-Segment-Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2015;131(21):1843-50. https://doi.org/10.1161/CIRCULATIONAHA.114.014145.

Kim TH, Yang PS, Kim D, Yu HT, Uhm JS, Kim JY, Pak HN, Lee MH, Joung B, Lip GYH. CHA2DS2-VASc Score for Identifying Truly Low-Risk Atrial Fibrillation for Stroke: A Korean Nationwide Cohort Study. Stroke. 2017;48(11):2984-2990. https://doi.org/10.1161/STROKEAHA.117.018551.

Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost. 2017;117(7):1230-1239. https://doi.org/10.1160/TH16-11-0876.

Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154(13):1449-1457. https://doi.org/10.1001/archinte.1994.00420130036007.

Stepina EV, Lukyanov MM, Bichurina MA, Belova EN, Kudryashov EV, Yuzkov YuV, Boytsov SA. Naznachenie medikamentoznoj terapii, vlijajushhej na prognoz u bolnyh s fibrilljaciej predserdij v sochetanii s arterialnoj gipertoniej, ishemicheskoj boleznju serdca, hronicheskoj serdechnoj nedostatochnostju po dannym registra REKVAZAKLINIKA [Prescription of medications influencing prognosis in atrial fibrillation with arterial hypertension, coronary heart disease, chronic heart failure, by the registry REKVAZA-CLINIC]. Kardiovaskuljarnaja terapija i profilaktika [Cardiovascular therapy and prevention]. 2017;16(2):33-38. https://doi.org/10.15829/1728-8800-2017-2-33-38. (Russian).

Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123(14):1501-1508. https://doi.org/10.1161/CIRCULATIONAHA.110.009035.

Sharashova E, Wilsgaard T, Ball J, Morseth B, Gerdts E, Hopstock LA, Mathiesen EB, Schirmer H, Løchen ML. Long-term blood pressure trajectories and incident atrial fibrillation in women and men: the Tromsø Study. Eur Heart J. 2020;41(16):1554-1562. https://doi.org/10.1093/eurheartj/ehz234.

Lee SS, Ae Kong K, Kim D, Lim YM, Yang PS, Yi JE, Kim M, Kwon K, Bum Pyun W, Joung B, Park J. Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea. Eur Heart J. 2017;38(34):2599-2607. https://doi.org/10.1093/eurheartj/ehx316.

Wijesurendra RS, Casadei B. Seek and Ye Shall Find Subclinical Atrial Fibrillation in High-Risk Elderly Patients. Circulation. 2017;136(14):1284-1287. https://doi.org/10.1161/CIRCULATIONAHA.117.029397.

Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013;167(5):1807-1824. https://doi.org/10.1016/j.ijcard.2012.12.093.

Lau YF, Yiu KH, Siu CW, Tse HF. Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications. J Hum Hypertens. 2012;26(10):563-569. https://doi.org/10.1038/jhh.2011.105.

Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, Goette A, Lewalter T, Ravens U, Meinertz T, Breithardt G, Steinbeck G. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11(4):423-434. https://doi.org/10.1093/europace/eun369.

Buchbinder W, Sugarman H. Arterial blood pressure in cases of auricular fibrillation, measured directly. Arch Intern Med. 1940;66(3):625-642. https://doi.org/10.1001/archinte.1940.00190150096007.

Olbers J, Gille A, Ljungman P, Rosenqvist M, Östergren J, Witt N. High beat-to-beat blood pressure variability in atrial fibrillation compared to sinus rhythm. Blood Press. 2018;27(5):249-255. https://doi.org/10.1080/08037051.2018.1436400.

Dornhorst AC, Howard P, Leathart GL. Respiratory variations in blood pressure. Circulation. 1952;6(4):553-558. https://doi.org/10.1161/01.cir.6.4.553.

Elstad M, Walløe L, Chon KH, Toska K. Low-frequency fluctuations in heart rate, cardiac output and mean arterial pressure in humans: what are the physiological relationships? J Hypertens. 2011;29(7):1327-1336. https://doi.org/10.1097/HJH.0b013e328347a17a.

Aletti F, Hammond RL, Sala-Mercado JA, Chen X, O’Leary DS, Baselli G, Mukkamala R. Cardiac output is not a significant source of low frequency mean arterial pressure variability. Physiol Meas. 2013;34(9):1207-1216. https://doi.org/10.1088/0967-3334/34/9/1207.

Bruno RM, Ghiadoni L, Seravalle G, Dell’oro R, Taddei S, Grassi G. Sympathetic regulation of vascular function in health and disease. Front Physiol. 2012;3:284. https://doi.org/10.3389/fphys.2012.00284.

Wasmund SL, Li JM, Page RL, Joglar JA, Kowal RC, Smith ML, Hamdan MH. Effect of atrial fibrillation and an irregular ventricular response on sympathetic nerve activity in human subjects. Circulation. 2003;107(15):2011-2015. https://doi.org/10.1161/01.CIR.0000064900.76674.CC.

Segerson NM, Sharma N, Smith ML, Wasmund SL, Kowal RC, Abedin M, Macgregor JF, Pai RK, Freedman RA, Klein RC, Wall TS, Stoddard G, Hamdan MH. The effects of rate and irregularity on sympathetic nerve activity in human subjects. Heart Rhythm. 2007;4(1):20-26. https://doi.org/10.1016/j.hrthm.2006.09.017.

Lieder H, Breithardt G, Heusch G. Fatal attraction - A brief pathophysiology of the interaction between atrial fibrillation and myocardial ischemia. Int J Cardiol. 2018;254:132-135. https://doi.org/10.1016/j.ijcard.2017.11.119.

Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol. 1997;30(4):1039-1045. https://doi.org/10.1016/s0735-1097(97)00254-4.

Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-952. https://doi.org/10.1016/S0140-6736(04)17018-9.

Li ZY, Taviani V, Tang T, Sadat U, Young V, Patterson A, Graves M, Gillard JH. The mechanical triggers of plaque rupture: shear stress vs pressure gradient. Br J Radiol. 2009;82(1):39-45. https://doi.org/10.1259/bjr/15036781.

Xiong H, Liu X, Tian X, Pu L, Zhang H, Lu M, Huang W, Zhang YT. A numerical study of the effect of varied blood pressure on the stability of carotid atherosclerotic plaque. Biomed Eng Online. 2014;13:152. https://doi.org/10.1186/1475-925X-13-152.

Lee SR, Choi YJ, Choi EK, Han KD, Lee E, Cha MJ, Oh S, Lip GYH. Blood Pressure Variability and Incidence of New-Onset Atrial Fibrillation: A Nationwide PopulationBased Study. Hypertension. 2020;75(2):309-315. https://doi.org/10.1161/HYPERTENSIONAHA.119.13708.

Nimtsovych TI, Kravchenko AM, Mishcheniuk OYu, Mikhaliev КО, Chursina TYa. Mizhvizytna variabelnist arterialnogo tysku u cholovikiv z arterialnoju gipertenzijeju, shho prozhyvajut u silskij miscevosti: zvjazok z fibryljacijeju peredserd neklapannogo genezu [Visit-to-visit blood pressure variability in rural males with arterial hypertension: association with non-valvular atrial fibrillation]. Klinichna ta profilaktychna medycyna [Clinical and preventive medicine]. 2020;2(12):90-109. https://doi.org/10.31612/2616-4868.2(12).2020.06. (Ukrainian).

Mehlum MH, Liestøl K, Wyller TB, Hua TA, Rostrup M, Berge E. Blood pressure variability in hypertensive patients with atrial fibrillation in the VALUE trial. Blood Press. 2019;28(2):77-83. https://doi.org/10.1080/08037051.2018.1524707.

Hijioka N, Kamioka M, Kazuaki A, Yamada S, Kaneshiro T, Ishida T, Takeishi Y. Visit-to-visit Blood Pressure Variability Predicts Recurrence of Atrial Fibrillation in Patients with Hypertension. Circulation. 2019;140(Suppl 1):11808. https://www.ahajournals.org/doi/abs/10.1161/circ.140.suppl_1.11808

Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017;14(11):627-628. https://doi.org/10.1038/nrcardio.2017.153.

Yalovenko MI, Khaniukov OO. Osoblyvosti perebigu arterialnoi gipertenzii v pacijentiv z ishemichnoju hvoroboju sercja ta fibryljacijeju peredserd [Features of the arterial hypertension clinical course in patients with ischemic heart disease and atrial fibrillation]. Medychni perspektyvy [Medical perspectives]. 2018;23(4):81-87. https://doi.org/10.26641/2307-404.2018.4.153005. (Ukrainian).

Thomas MC, Dublin S, Kaplan RC, Glazer NL, Lumley T, Longstreth WT Jr, Smith NL, Psaty BM, Siscovick DS, Heckbert SR. Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens. 2008;21(10):1111-1116. https://doi.org/10.1038/ajh.2008.248.

Marott SC, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J. 2014;35(18):1205-1214. https://doi.org/10.1093/eurheartj/eht507.

Kim D, Yang PS, Kim TH, Jang E, Shin H, Kim HY, Yu HT, Uhm JS, Kim JY, Pak HN, Lee MH, Joung B, Lip GYH. Ideal Blood Pressure in Patients with Atrial Fibrillation. J Am Coll Cardiol. 2018;72(11):1233-1245. https://doi.org/10.1016/j.jacc.2018.05.076.

Hiremath S, Vala DR, Roy T, Khera P, Kaul U. Changing patterns in the prevalence and management of cardiovascular risk factors in India and their comparison with the rest of the world along with clinical outcomes at 5-year: An analysis of stable coronary artery disease patients from The Prospective Observational Longitudinal Registry of patients with stable coronary artery disease (CLARIFY) registry. Indian Heart J. 2018;70(Suppl 3):S36-S42. https://doi.org/10.1016/j.ihj.2018.04.003.

Parcha V, Patel N, Kalra R, Kim J, Gutiérrez OM, Arora G, Arora P. Incidence and Implications of Atrial Fibrillation/Flutter in Hypertension: Insights From the SPRINT Trial. Hypertension. 2020;75(6):1483-1490. https://doi.org/10.1161/HYPERTENSIONAHA.120.14690.

Webb AJ, Rothwell PM. Blood pressure variability and risk of new-onset atrial fibrillation: a systematic review of randomized trials of antihypertensive drugs. Stroke. 2010;41(9):2091-2093. https://doi.org/10.1161/STROKEAHA.110.589531.

Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-2031. https://doi.org/10.1016/S0140-6736(04)16451-9.

Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45(5):712-719. https://doi.org/10.1016/j.jacc.2004.10.068.

Emdin CA, Anderson SG, Salimi-Khorshidi G, Woodward M, MacMahon S, Dwyer T, Rahimi K. Usual blood pressure, atrial fibrillation and vascular risk: evidence from 4.3 million adults. Int J Epidemiol. 2017;46(1):162-172. https://doi.org/10.1093/ije/dyw053.

Zhao D, Wang ZM, Wang LS. Prevention of atrial fibrillation with renin-angiotensin system inhibitors on essential hypertensive patients: a meta-analysis of randomized controlled trials. J Biomed Res. 2015;29(6):475-85. https://doi.org/10.7555/JBR.29.20140149.

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32(12):2285-2295. https://doi.org/10.1097/HJH.0000000000000378.

Boev SS, Dotsenko NYa, Shekhunova IA, Gerasimenko LV. Rol variabelnosti arterialnogo davlenija pri arterialnoj gipertenzii v razvitii kognitivnyh narushenij [The role of blood pressure variability in hypertension in the development of cognitive impairment]. Arterіalna gіpertenzіja [Hypertension]. 2019;2:25-30. https://doi.org/10.22141/2224-1485.2.64.2019.168751. (Russian).

Messerli FH, Fischer U, Rimoldi SF, Bangalore S. Hypertension control and cardiovascular disease. Lancet. 2017;389(10065):153. https://doi.org/10.1016/S0140-6736(17)30017-X.




Загрузок PDF: 131
Опубликован
2021-11-02
Как цитировать
1.
Боев СС, Доценко НЯ, Шехунова ИА, Герасименко ЛВ, Яценко ОВ, Любитов ДЮ. ВАРИАБЕЛЬНОСТЬ АРТЕРИАЛЬНОГО ДАВЛЕНИЯ ПРИ КОМОРБИДНОСТИ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ И ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ. Журнал ГрГМУ (Journal GrSMU) [Интернет]. 2 ноябрь 2021 г. [цитируется по 6 октябрь 2022 г.];19(5):481-8. доступно на: http://journal-grsmu.by/index.php/ojs/article/view/2697